quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:10:24·49d
SECFiling
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

LCTX· Lineage Cell Therapeutics Inc.
Health Care
Original source

Companies

  • LCTX
    Lineage Cell Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Aug 20UpdateCraig Hallum$4.00
  • Nov 2UpdateRobert W. Baird$5.00
  • Jun 14UpdateB. Riley Securities$4.00
  • Aug 19UpdateNoble Capital Markets$8.00

Related

  • PR11d
    Lineage Announces Formation of Scientific Advisory Board
  • PR14d
    Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
  • PR31d
    Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
  • SEC31d
    SEC Form EFFECT filed by Lineage Cell Therapeutics Inc.
  • INSIDER42d
    President and CEO Culley Brian M bought $24,375 worth of shares (15,000 units at $1.62), increasing direct ownership by 6% to 255,516 units (SEC Form 4)
  • SEC44d
    SEC Form S-3 filed by Lineage Cell Therapeutics Inc.
  • SEC44d
    Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • SEC44d
    SEC Form 424B5 filed by Lineage Cell Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022